| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
20,611 |
18,110 |
$1.32M |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
24,086 |
5,756 |
$935K |
| 87481 |
|
17,565 |
5,150 |
$316K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
3,397 |
2,917 |
$272K |
| 87150 |
|
4,470 |
1,817 |
$194K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
6,223 |
1,667 |
$93K |
| 87529 |
|
6,802 |
4,067 |
$84K |
| 87563 |
|
8,234 |
5,178 |
$50K |
| 87511 |
|
6,103 |
4,117 |
$49K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
18,151 |
15,979 |
$42K |
| 87496 |
|
6,362 |
4,228 |
$41K |
| 87653 |
|
8,270 |
5,133 |
$39K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
6,583 |
4,399 |
$39K |
| 87640 |
|
6,758 |
4,675 |
$32K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
5,812 |
3,932 |
$19K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
6,498 |
4,334 |
$18K |
| 87641 |
|
2,381 |
1,753 |
$14K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
234 |
210 |
$11K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
1,463 |
1,229 |
$10K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,368 |
1,142 |
$8K |
| G2024 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source |
420 |
224 |
$4K |
| 88141 |
|
1,463 |
1,229 |
$3K |
| 81005 |
|
2,321 |
2,170 |
$1K |
| 81514 |
|
169 |
155 |
$1K |
| 87500 |
|
615 |
453 |
$512.84 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
286 |
158 |
$193.53 |
| 88291 |
|
16 |
16 |
$173.94 |